drugset

drugset / Trial / NCT04959305

A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension

NCT04959305 ↗

Phase 2 Completed 245 enrolled Hanmi Pharmaceutical Company Limited

RandomizedParallel-groupDouble-blindTreatment

Summary

A multicenter, randomized, double-blind, parallel, phase 2 study to explore the dose of HCP1803 in patients with essential hypertension

Timeline

Start: 2021-04-22
Primary completion: 2022-02-28
Completion: 2022-02-28

Publications

Sung KC, Hong SJ, Rhee MY, Jeong MH, Kim DH, Lim SW, Park K, Lee JB, Kim SY, Cho JM, Cho GY, Heo JH, Kim SH, Lee HY, Kim W, Cho DK, Park S, Shin J, Pyun WB, Kwon K, Rha SW, Jung JA. Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension. J Clin Hypertens (Greenwich). 2023 May;25(5):429-439. doi: 10.1111/jch.14656. Epub 2023 Apr 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HCP1803-3	Unknown	—	Oral
Comparator	RLD2003	Unknown	—	Oral
Comparator	RLD2004	Unknown	—	Oral
Comparator	RLD2005	Unknown	—	Oral

Indications